Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

Protective associations were seen between GLP-1 RA use and colon and rectal cancers. "Our results suggest [GLP-1 RAs] may modestly cut the chance of developing certain cancers—especially cancers ...

“These findings expand upon the growing body of literature raising concerns regarding the potential ocular safety of systemic GLP-1 RA use in patients with diabetes,” researchers ...

Data were included for 85,015 adults with a body mass index ≥30 kg/m 2 and a diagnosis of diabetes who newly initiated a GLP-1 RA or DPP-4 inhibitor between 2013 and 2023. Patients prescribed ...

In a move that could reshape how doctors approach both weight and heart health, the American College of Cardiology (ACC) ...

Logistic regression models were utilized to control for potential confounders such as sex, reporter type, number of suspect drugs, and suspected GLP-1 RA agents. Data analysis categorized 5 ...

“Because adverse effects are more prevalent at higher GLP-1 RA doses, discontinuation of these medications might lead to a high likelihood of side effects upon medication reinitiation or require ...

5 ICON carried out a study to assess changes in payer coverage and inform current patient access to GLP-1 RA use in weight loss. This descriptive retrospective analysis used ICON’s Symphony ...

In 2024, 4% of U.S. adults were prescribed a GLP-1 therapy — a 363.7% increase from 0.9% in 2019, according to a Fair Health analysis of more than 51 billion commercial claim records.

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related cancers, especially colorectal cancer, according to data released on Thursday ...